Ascitic complement system in ovarian cancer

British Journal of Cancer

Volumn 92, Issue 5, 2005, Pages 895-905

  Bjorge L ^a,b,c,e   Hakulinen, J ^a   Vintermyr, O K ^c   Jarva, H ^a   Jensen, T S ^b   Iversen, O E ^b   Meri, S ^a,d  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF BERGEN   (Norway)

^c HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^e HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

Ascitic fluid; Complement; Immunosurveillance; Immunotherapy; Ovarian neoplasm

Indexed keywords

CD59 ANTIGEN; CHROMIUM 51; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C4; COMPLEMENT COMPONENT C5B; COMPLEMENT COMPONENT C9; COMPLEMENT FACTOR H; DECAY ACCELERATING FACTOR; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MEMBRANE COFACTOR PROTEIN;

ADULT; AGED; ARTICLE; ASCITES; ASCITES FLUID; CANCER CELL; CLINICAL ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; FEMALE; HEMOLYSIS; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; OVARY CANCER; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL;

ADENOCARCINOMA; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, CD59; ASCITES; CELL LINE, TUMOR; COMPLEMENT C3; COMPLEMENT C4; COMPLEMENT SYSTEM PROTEINS; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MIDDLE AGED; OVARIAN NEOPLASMS;

EID: 16244406519     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602334     Document Type: Article

References (53)

1. Abendstein B, Marth C, Muller-Holzner E, Widschwendter M, Daxenbichler G, Zeimet AG (2000) Clinical significance of serum and ascitic p53 autoantibodies in epithelial ovarian carcinoma. Cancer 88: 1432-1437
2. Alexandrakis MG, Kyriakou D, Koutroubakis IE, Alexandraki R, Vlachonikolis IG, Eliopoulos GD (2001) Assaying of tumour necrosis factor alpha, complement factors, and alpha-1-antitrypsin in the diagnosis of malignant serous effusions. Am J Clin Oncol 24: 562-565
3. Baekelandt MM, Holm R, Nesland JM, Trope CG, Kristensen GB (2000) P-glycoprotein expression is a marker for chemotherapy resistance and prognosis in advanced ovarian cancer. Anticancer Res 20: 1061-1067
4. Bjørge L, Hakulinen J, Wahlstrom T, Matre R, Meri S (1997a) Complement-regulatory proteins in ovarian malignancies. Int J Cancer 70: 14-25
5. Bjørge L, Jensen TS, Matre R (1996) Characterisation of the complement-regulatory proteins decay-accelerating factor (DAF, CD55) and membrane cofactor protein (MCP, CD46) on a human colonic adenocarcinoma cell line. Cancer Immunol Immunother 42: 185-192
6. Bjørge L, Junnikkala S, Kristoffersen EK, Hakulinen J, Matre R, Meri S (1997b) Resistance of ovarian teratocarcinoma cell spheroids to complement-mediated lysis. Br J Cancer 75: 1247-1255
7. Bjørge L, Vedeler CA, Ulvestad E, Matre R (1994) Expression and function of CD59 on colonic adenocarcinoma cells. Eur J Immunol 24: 1597-1603
8. Bjørge T, Engeland A, Hansen S, Trope CG (1998) Prognosis of patients with ovarian cancer and borderline tumours diagnosed in Norway between 1954 and 1993. Int J Cancer 75: 663-670
9. Chinni SR, Falchetto R, Gercel-Taylor C, Shabanowitz J, Hunt DF, Taylor DD (1997) Humoral immune responses to cathepsin D and glucose-regulated protein 78 in ovarian cancer patients. Clin Cancer Res 3: 1557-1564
10. Dillman RO (1994) Antibodies as cytotoxic therapy. J Clin Oncol 12: 1497-1515
11. FIGO (1987) International Federation of Gynecology and Obstetrics. Changes in definition of clinical staging of the cervix and ovary. Am J Obstet Gynecol 156: 263-264
12. Fleuren GJ, Gorter A, Kuppen PJ, Litvinov S, Warnaar SO (1995) Tumour heterogeneity and immunotherapy of cancer. Immunol Rev 145: 91-122
13. Gercel-Taylor C, Bazzett LB, Taylor DD (2001) Presence of aberrant tumour-reactive immunoglobulins in the circulation of patients with ovarian cancer. Gynecol Oncol 81: 71-76
14. Golay J, Zaffaroni L, Vaccari T, Lazzari M, Borleri GM, Bernasconi S, Tedesco F, Rambaldi A, Introna M (2000) Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 95: 3900-3908
15. Gorter A, Meri S (1999) Immune evasion of tumour cells using membrane-bound complement regulatory proteins. Immunol Today 20: 576-582
16. Gruber R, Holz E, Riethmuller G (1996) Monoclonal antibodies in cancer therapy. Springer Semin Immunopathol 18: 243-251
17. Guzman J, Hilgarth M, Bross KJ, Wiehle U, Ross A, Kresin V, Costabel U (1988) Lymphocyte subpopulations in malignant ascites of serous papillary ovarian adenocarcinoma. An immunocytochemical study. Acta Cytol 32: 811-815
18. Hakulinen J, Junnikkala S, Sorsa T, Meri S (2004) Complement inhibitor membrane cofactor protein (MCP; CD46) is constitutively shed from cancer cell membranes in vesicles and converted by a metalloproteinase to a functionally active soluble form. Eur J Immunol 34: 2620-2629
19. Hakulinen J, Meri S (1994) Expression and function of the complement membrane attack complex inhibitor protectin (CD59) on human breast cancer cells. Lab Invest 71: 820-827
20. Hakulinen J, Meri S (1995) Shedding and enrichment of the glycolipid-anchored complement lysis inhibitor protectin (CD59) into milk fat globules. Immunology 85: 495-501
21. Hakulinen J, Meri S (1998) Complement-mediated killing of microtumors in vitro. Am J Pathol 153: 845-855
22. Harjunpaa A, Junnikkala S, Meri S (2000) Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms. Scand J Immunol 51: 634-641
23. Junnikkala S, Jokiranta TS, Friese MA, Jarva H, Zipfel PF, Meri S (2000) Exceptional resistance of human H2 glioblastoma cells to complement-mediated killing by expression and utilization of factor H and factor H-like protein 1. J Immunol 164: 6075-6081
24. Junnikkala S, Hakulinen J, Jarva H, Manuelian T, Bjørge L, Butzow R, Zipfel PF, Meri S (2002) Secretion of soluble complement inhibitors factor H and factor H-like protein (FHL-1) by ovarian tumour cells. Br J Cancer 87: 1119-1127
25. Jurianz K, Ziegler S, Garcia-Schuler H, Kraus S, Bohana-Kashtan O, Fishelson Z, Kirschfink M (1999) Complement resistance of tumour cells: basal and induced mechanisms. Mol Immunol 36: 929-939
26. Kawata M, Sekiya S (1998) Detection of epithelial ovarian-cancer- associated antigens involved in immune complexes by monoclonal antibodies. Tumour Biol 19: 1-11
27. Lehto T, Meri S (1993) Interactions of soluble CD59 with the terminal complement complexes. CD59 and C9 compete for a nascent epitope on C8. J Immunol 151: 4941-4949
28. Lucas SD, Karlsson-Parra A, Nilsson B, Grimelius L, Akerstrom G, Rastad J, Juhlin C (1996) Tumour-specific deposition of immunoglobulin G and complement in papillary thyroid carcinoma. Hum Pathol 27: 1329-1335
29. Magyarlaki T, Mosolits S, Baranyay F, Buzogany I (1996) Immunohistochemistry of complement response on human renal cell carcinoma biopsies. Tumori 82: 473-479
30. Mal F, Huu TP, Bendahou M, Trinchet JC, Gamier M, Hakim J, Beaugrand M (1991) Chemoattractant and opsonic activity in ascitic fluid. A study in 47 patients with cirrhosis or malignant peritonitis. J Hepatol 12: 45-49
31. Maloney DG, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, Janakiraman N, Foon KA, Liles TM, Dallaire BK, Wey K, Royston I, Davis T, Levy R (1997) IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90: 2188-2195
32. Markman M (1998) Intraperitoneal therapy of ovarian cancer. Semin Oncol 25: 356-360
33. Matsumoto M, Takeda J, Inoue N, Hara T, Hatanaka M, Takahashi K, Nagasawa S, Akedo H, Seya T (1997) A novel protein that participates in nonself discrimination of malignant cells by homologous complement. Nat Med 3: 1266-1270
34. Morgan BP (1992) Effects of the membrane attack complex of complement on nucleated cells. Curr Top Microbiol Immunol 178: 115-140
35. Morgan BP, Meri S (1994) Membrane proteins that protect against complement lysis. Springer Semin Immunopathol 15: 369-396
36. Nakamura K, Nariuchi H, Nanba K (1978) Antibody forming cell precursors among glass-adherent peritoneal exudate cells. Immunol Commun 7: 441-459
37. Niculescu F, Rus HG, Retegan M, Vlaicu R (1992) Persistent complement activation on tumour cells in breast cancer. Am J Pathol 140: 1039-1043
38. Ng T, Pagliuca A, Mufti GJ (2002) Intraperitoneal rituximab: an effective measure to control recurrent abdominal ascites due to non-Hodgkin's lymphoma. Ann Hematol 81: 405-406
39. Parsons SL, Watson SA, Steele RJ (1996) Malignant ascites. Br J Surg 83: 6-14
40. Pisani P, Bray F, Parkin DM (2002) Estimates of the world-wide prevalence of cancer for 25 sites in the adult population. Int J Cancer 97: 72-81
41. Rao GS, Hanjani P (1988) Detection of human ovarian tumour-associated antigens by antibodies isolated from ovarian carcinoma ascitic fluid. Am J Obstet Gynecol 159: 94-98
42. Rooney IA, Atkinson JP, Krul ES, Schonfeld G, Polakoski K, Saffitz JE, Morgan BP (1993) Physiologic relevance of the membrane attack complex inhibitory protein CD59 in human seminal plasma: CD59 is present on extracellular organelles (prostasomes), binds cell membranes, and inhibits complement-mediated lysis. J Exp Med 177: 1409-1420
43. Rooney IA, Morgan BP (1992) Characterization of the membrane attack complex inhibitory protein CD59 antigen on human amniotic cells and in amniotic fluid. Immunology 76: 541-547
44. Rubin SC (1993) Monoclonal antibodies in the management of ovarian cancer. A clinical perspective. Cancer 71(4 Suppl): 1602-1612
45. Runowicz CD, Cohen CJ, Adelsberg BR (1989) Immune complexes in ovarian carcinoma. Gynecol Oncol 32: 350-353
46. Runyon BA, Morrissey RL, Hoefs JC, Wyle FA (1985) Opsonic activity of human ascitic fluid: a potentially important protective mechanism against spontaneous bacterial peritonitis. Hepatology 5: 634-637
47. Silburn PA, Khoo SK, Daunter B, Hill R, Roberts TK, Mackay EV (1983) Types of immune complexes in the ascitic fluid of women with carcinoma of the ovary. Int Arch Allergy Appl Immunol 71: 219-223
48. Silburn PA, Khoo SK, Hill R, Daunter B, Mackay EV (1984a) Demonstration of tumour-associated immunoglobulin G isolated from immune complexes in ascitic fluid of ovarian cancer. Diagn Immunol 2: 30-35
49. Silburn PA, Neil JC, Khoo SK, Daunter B, Hill R, Collins RJ, Mackay EV (1984b) Immune complexes in ovarian cancer: association between IgM class complexes and antinuclear autoantibodies in ascitic fluid. Int Arch Allergy Appl Immunol 74: 63-66
50. Taylor DD, Gercel-Taylor C (1998) Tumour-reactive immunoglobulins in ovarian cancer: diagnostic and therapeutic significance? (review). Oncol Rep 5: 1519-1524
51. Walport MJ (2001) Complement. First of two parts. N Engl J Med 344: 1058-1066
52. Yamakawa M, Yamada K, Tsuge T, Ohrui H, Ogata T, Dobashi M, Imai Y (1994) Protection of thyroid cancer cells by complement-regulatory factors. Cancer 73: 2808-2817
53. Zeimet AG, Widschwendter M, Knabbe C, Fuchs D, Herold M, Muller-Holzner E, Daxenbichler G, Offner FA, Dapunt O, Marth C (1998) Ascitic interleukin-12 is an independent prognostic factor in ovarian cancer. J Clin Oncol 16: 1861-1868